drugset / Trial / NCT03436615
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
RandomizedSequentialDouble-blindTreatment
Summary
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Timeline
- Start
- 2018-01-24
- Primary completion
- 2018-11-03
- Completion
- 2018-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BERDAZIMER SODIUM | Small molecule | 4 % | Topical |
| Subject | BERDAZIMER SODIUM | Small molecule | 8 % | Topical |
| Subject | BERDAZIMER SODIUM | Small molecule | 12 % | Topical |